JP2000510858A5 - - Google Patents

Download PDF

Info

Publication number
JP2000510858A5
JP2000510858A5 JP1997541562A JP54156297A JP2000510858A5 JP 2000510858 A5 JP2000510858 A5 JP 2000510858A5 JP 1997541562 A JP1997541562 A JP 1997541562A JP 54156297 A JP54156297 A JP 54156297A JP 2000510858 A5 JP2000510858 A5 JP 2000510858A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1997541562A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000510858A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP1997/002632 external-priority patent/WO1997044043A1/en
Publication of JP2000510858A publication Critical patent/JP2000510858A/ja
Publication of JP2000510858A5 publication Critical patent/JP2000510858A5/ja
Pending legal-status Critical Current

Links

JP09541562A 1996-05-23 1997-05-22 6―フルオロウルソデオキシコール酸(6―fudca)による結腸直腸癌の予防および治療 Pending JP2000510858A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1820296P 1996-05-23 1996-05-23
US60/018,202 1996-05-23
PCT/EP1997/002632 WO1997044043A1 (en) 1996-05-23 1997-05-22 Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-fudca)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009252071A Division JP2010059175A (ja) 1996-05-23 2009-11-02 6−フルオロウルソデオキシコール酸(6−fudca)を含む結腸腺腫または結腸微小腺腫の処置または進行の遅延用医薬組成物

Publications (2)

Publication Number Publication Date
JP2000510858A JP2000510858A (ja) 2000-08-22
JP2000510858A5 true JP2000510858A5 (2) 2004-12-09

Family

ID=21786767

Family Applications (2)

Application Number Title Priority Date Filing Date
JP09541562A Pending JP2000510858A (ja) 1996-05-23 1997-05-22 6―フルオロウルソデオキシコール酸(6―fudca)による結腸直腸癌の予防および治療
JP2009252071A Withdrawn JP2010059175A (ja) 1996-05-23 2009-11-02 6−フルオロウルソデオキシコール酸(6−fudca)を含む結腸腺腫または結腸微小腺腫の処置または進行の遅延用医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009252071A Withdrawn JP2010059175A (ja) 1996-05-23 2009-11-02 6−フルオロウルソデオキシコール酸(6−fudca)を含む結腸腺腫または結腸微小腺腫の処置または進行の遅延用医薬組成物

Country Status (10)

Country Link
US (1) US6426340B1 (2)
EP (1) EP0906106B1 (2)
JP (2) JP2000510858A (2)
AT (1) ATE394107T1 (2)
AU (1) AU3091597A (2)
CA (1) CA2253593C (2)
DE (1) DE69738667D1 (2)
ES (1) ES2306459T3 (2)
PT (1) PT906106E (2)
WO (1) WO1997044043A1 (2)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU758679B2 (en) * 1998-07-24 2003-03-27 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
EP1105141B1 (de) * 1998-08-06 2003-11-05 Wolfgang Stremmel Phosphatidylcholin als arzneimittel mit schleimhautschützender wirkung
RS50303B (sr) * 1999-09-28 2009-09-08 Panacea Biotec Limited, Farmaceutska kompozicija nimesulida sa kontrolisanim oslobađanjem
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
AU2003287300A1 (en) * 2002-11-01 2004-06-07 James Kaput Identification of diet-regulated disease-associated genes
WO2008088836A2 (en) * 2007-01-16 2008-07-24 The Burnham Institute For Medical Research Compositions and methods for treatment of colorectal cancer
EP2255813A1 (en) * 2009-05-29 2010-12-01 The Royal College of Surgeons in Ireland Derivatives of ursodeoxycholic acid for the treatment of diarrhoea
PL3400944T3 (pl) 2010-11-04 2020-11-16 Albireo Ab Inhibitory ibat w leczeniu chorób wątroby
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
JP2020530448A (ja) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES2942443T3 (es) 2018-06-05 2023-06-01 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
BR112020024479A2 (pt) 2018-06-20 2021-03-02 Albireo Ab hidrato cristalino, modificações cristalinas de odevixibat, solvato misto de odevixibat, uso de modificação cristalina de odevixibat, processo para a preparação de modificação cristalina de odevixibat, e, composição farmacêutica
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
HUE060905T2 (hu) 2019-02-06 2023-04-28 Albireo Ab Benzotiadiazepin vegyületek és azok alkalmazása epesav modulátorként
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
ES2973549T3 (es) 2019-12-04 2024-06-20 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores de los ácidos biliares
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
EP4188541B1 (en) 2020-08-03 2024-12-25 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023549226A (ja) 2020-11-12 2023-11-22 アルビレオ エービー 進行性家族性肝内胆汁うっ滞症(pfic)を処置するためのオデビキシバット
JP2024500309A (ja) 2020-12-04 2024-01-09 アルビレオ エービー ベンゾチア(ジ)アゼピン化合物および胆汁酸モジュレータとしてのその使用
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8825526D0 (en) * 1988-11-01 1988-12-07 Enzymatix Ltd Diagnosis
US5175320A (en) * 1989-04-17 1992-12-29 Giuliani S.P.A. Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US5843929A (en) 1996-03-22 1998-12-01 Mayo Foundation For Medical Education And Research Chemoprevention of metachronous adenomatous colorectal polyps

Similar Documents

Publication Publication Date Title
JP2000502280A5 (2)
JP2001505442A5 (2)
JP2000501771A5 (2)
JP2000501599A5 (2)
JP2000501018A5 (2)
JP2001501503A5 (2)
JP2000501324A5 (2)
JP2000502472A5 (2)
JP2000501825A5 (2)
JP2000501338A5 (2)
JP2000500874A5 (2)
JP2000516223A5 (2)
JP2001505746A5 (2)
JP2000502485A5 (2)
JP2000502425A5 (2)
JP2000502568A5 (2)
JP2000501774A5 (2)
JP2000500912A5 (2)
JP2000502570A5 (2)
JP2000501876A5 (2)
JP2001507143A5 (2)
JP2000510858A5 (2)
JP2000501744A5 (2)
JP2000501229A5 (2)
JP2001500380A5 (2)